Basepoint Wealth’s Edwards Lifesciences EW Stock Holding History

Basepoint Wealth’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$724	Hold	8	–	–	﹤0.01%	590
2026 Q1	$641	Hold	8	–	–	﹤0.01%	605
2025 Q4	$682	Buy	+8	New	+$657	﹤0.01%	573

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Basepoint Wealth's EW Position: Q2 2026 in Review

Basepoint Wealth held its Edwards Lifesciences (EW) position steady in Q2 2026 at 8 shares worth $724. The position accounts for ﹤0.01% of the portfolio, ranked #590.

Basepoint Wealth first reported a position in EW in Q4 2025 and has held it in 3 quarters since. 1,333 funds tracked by Wall St. Rank hold EW as of Q2 2026.

Basepoint Wealth held 8 shares of Edwards Lifesciences worth $724 as of Q2 2026.
Basepoint Wealth left its Edwards Lifesciences share count unchanged in Q2 2026.
Edwards Lifesciences made up ﹤0.01% of Basepoint Wealth's portfolio in Q2 2026, its #590 holding.
Basepoint Wealth first reported a position in Edwards Lifesciences in Q4 2025 and has held it in 3 quarters since.
1,333 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Basepoint Wealth's 13F filing for Q2 2026, filed 10 Aug 2026.